Healthcare Industry News: influenza
News Release - September 24, 2007
Additional Studies Further Demonstrate Safety and Efficacy of PuriCore's Vashe(TM) Wound Therapy SystemMore than 2,000 patients successfully treated including five with necrotizing fasciitis
MALVERN, PENNSYLVANIA, AND STAFFORD, UK, September 24, 2007-PuriCore (LSE:PURI.L ), the life sciences company focused on the control of infectious pathogens with its novel, safe antimicrobial technology, today announced new clinical results from successful case studies showing the safety and efficacy of its FDA-cleared Vashe Wound Therapy Solution in a variety of clinical applications. To date, nine physicians at 13 US clinical sites have used Vashe successfully to treat more than 2,000 patients with a diverse range of chronic and acute wounds with no report of adverse effects. The Vashe System produces hypochlorous acid at near-neutral pH, the same antimicrobial solution produced by the human body to fight infection.
The clinicians reported positive results and efficacy of Vashe for the treatment of a variety of challenging wounds including chronic venous ulcers; non-healing surgical wounds; and necrotizing fasciitis, a rare, life-threatening bacterial infection of the skin, subcutaneous tissue, and superficial facia with a mortality rate of 20 to 60%. Five patients suffering from necrotizing fasciitis were successfully treated with the Vashe Solution.
These and other positive clinical results were presented at the New Cardiovascular Horizons and Management of the Diabetic Foot & Wound Healing Conference in New Orleans, LA, September 5-8, and will be presented this week at Georgetown University Hospital's Diabetic Limb Salvage Conference in Washington, DC. Previously, studies conducted on patients with chronic venous ulcers at the University of Oxford in England that were published in the Journal of Wound Care showed a positive and observable improvement in healing rates and pain reduction with the use of the Vashe Solution.
"We are very pleased with these promising early clinical results for the Vashe Solution showing its safety and potential therapeutic value in the management of such a wide variety of chronic and acute wounds," said Greg Bosch, CEO of PuriCore.
To date, all clinicians were un-paid, and these studies being conducted are investigator-driven and non-controlled. PuriCore plans to continue clinical work to demonstrate the efficacy of Vashe in a broad range of applications, including initiation of a randomized pilot study focused on post-operative burn management.
The Vashe Wound Therapy System is a novel, noninvasive, easy-to-use wound treatment process that has been shown to be complementary to existing treatment methods. The Vashe System is an FDA-cleared medical device used for moistening, irrigating, cleaning, and debriding acute and chronic wounds including stage I through IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first and second degree burns, abrasions, and minor irritations of the skin. The Vashe Solution mimics the human body's own infection fighter, hypochlorous acid, to eliminate pathogens that produce harmful toxins and odor and cause significant pain-all without any tissue damage.
PuriCore (LSE:PURI.L ) is a life sciences company focused on developing and commercializing proprietary products that safely, effectively, and naturally kill contagious pathogens. PuriCore's technology provides a solution to a broad range of markets that depend upon controlling contamination, including food safety, medical device disinfection, wound therapy, and hospitality. The Company's proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores. Deploying hypochlorous acid solutions as soaks, sprays, mists, and in other forms, PuriCore's technology is designed to limit the spread of infectious disease, including major public health threats of M. tuberculosis, MRSA, E.coli, norovirus, avian influenza, HIV, polio virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK.
To receive additional information on PuriCore, please visit our web site at www.puricore.com, which does not form part of this press release.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.